A Study of RC48-ADC(Antibody Drug Conjugate) and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects With Locally Advanced or Metastatic Urothelial Cancer
NCT04264936
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
UNKNOWN
Status
36
Enrollment
OTHER
Sponsor class
Conditions
Urothelial Carcinoma
Interventions
DRUG:
RC48-ADC and JS001
Sponsor
Peking University Cancer Hospital & Institute